Pharmaceutical

Cambridge University and GSK sign immunology R&D collaboration

GSK has announced a £50m ($54.3m) investment in a partnership with the University of Cambridge to expedite R&D in immune-related diseases.

Oct 22, 2024 - 04:00
Cambridge University and GSK sign immunology R&D collaboration
GSK has announced a £50m ($54.3m) investment in a partnership with the University of Cambridge to expedite R&D in immune-related diseases.
Read the original article

Tags:

Previous Article

FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment

Next Article

Thermo Fisher’s Oncomine gains FDA approval as brain tumor diagnostic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Ohio has enshrined the right to an abortion. But major obstacles remain for patients and providers

Opinion: Ohio has enshrined the right to an abortion. B...

Nov 13, 2023

STAT+: For-profit health system’s Mass. hospitals teetering on the brink of financial disaster

STAT+: For-profit health system’s Mass. hospitals teete...

Mar 13, 2024

Immune-Onc’s antibody therapy collects second FDA orphan designation

Immune-Onc’s antibody therapy collects second FDA orpha...

Feb 22, 2024